Suzhou Chengyao Biotechnology Co., Ltd. (domestic capital) is headquartered in Biobay, Suzhou Industrial Park. With bioanalysis and pharmacokinetic research as its core business, Chengyao provides high-quality and efficient technical services for bioanalysis and pharmacokinetic evaluation from preclinical to clinical trials for the domestic and global pharmaceutical industry.

 At present, the company's core technical team serves more than 200 customers. The core members have worked in Shanghai Institute of Materia Medica, WuXi PharmaTech, and Suzhou Haike. He is proficient in domestic and foreign bioanalysis regulations and quality systems, and has rich experience in passing NMPA inspections. He has presided over and completed the bioanalysis and pharmacokinetic evaluation of 20 approved Class 1.1 new drugs and 100 generic drugs.

 The bioanalysis services provided by Chengyao include concentration analysis of small molecule chemicals, peptides, antibodies and other macromolecular drugs and biomarkers in biological matrices by mass spectrometry and enzyme-linked immunosorbent assay. Featured bioanalysis services include: liposome drugs, albumin drugs, derivatization analysis, inhalation preparations, in vitro drug preparations, chiral chromatography resolution, endogenous drugs, clinical dried blood spot samples for infants, peptides, PDC, ADC, nucleic acid drugs, etc. Other analysis services include: immunogenicity (ADA) research, flow cytometry analysis, ICP-OES/MS metal ion analysis.

 Chengyao’s pharmacokinetic evaluation business includes: clinical and non-clinical pharmacokinetics (ADME) of innovative drugs, pharmacokinetic evaluation (PK calculation, equivalence evaluation, DDI evaluation, dose linear relationship, food impact evaluation, non-radioactive quality Balance studies, etc.), quantitative pharmacology studies (population pharmacokinetics, PK/PD correlation, ER analysis, first dose calculation, etc.).